A federal jury in Connecticut found Ryan Fields, owner of pinnedaminos.com and projectaminos.com, guilty on 18 September 2026 of conspiring to sell misbranded and unapproved drugs and of money-laundering conspiracy. The prosecution's theory was that the "research use only" disclaimer on the site and the "not for human consumption" labels were themselves the deception, because the sellers gave customers dosing directions and health claims in a private Facebook group. The jury accepted it. Fields has not been sentenced; his co-defendant pleaded guilty and received three years of probation. It is a jury verdict, not a plea, which makes it a firmer precedent than the Paradigm Peptides case.
The website said the products were for laboratory and research use only. The labels said not for human consumption. In a private Facebook group, the people who wrote those labels were telling customers how much to take. On 18 September 2026 a federal jury decided the disclaimer was the fraud.
Ryan Fields, 52, of Port Neches, Texas, was found guilty in New Haven of conspiring to introduce misbranded and unapproved drugs into interstate commerce and to smuggle goods into the United States, and of conspiring to commit money laundering. With Lisa Mahan, 56, formerly of Glastonbury, Connecticut, he ran pinnedaminos.com, projectaminos.com and a private Facebook group called Pinned Aminos from September 2021 to June 2023. The Justice Department puts the operation at more than 10,000 parcels and more than $1.4 million, spent on cars and a house in Texas. Both were arrested on 23 August 2023.
Mahan pleaded guilty to the conspiracy charge on 6 April 2026 and was sentenced on 13 August 2026 to three years of probation. Fields went to trial and lost. He is on bond, and as of this writing no sentencing date has been set. The jury also ordered the forfeiture of the Texas house and a vehicle bought with the proceeds.
What the jury was asked to decide.
The charge was not that Pinned Aminos sold peptides. It was that the sellers knew the products were drugs for human use, sold them without prescriptions, imported some of them from foreign manufacturers, and dressed the whole thing in language designed to keep FDA away.
The Justice Department's own wording is the part worth reading twice. The disclaimer that products were "intended for laboratory and research use only" and "not intended for human ingestion" existed, in the prosecutors' words, "to avoid detection and mislead the FDA." The labels calling the products "research compounds" and "not for human consumption" were described the same way: false statements, not safe harbours.
What defeated the disclaimer was the sellers' own output. Through emails and posts in the Facebook group, Fields and Mahan gave customers information on the health benefits of what they were selling and directions on dosage. A seller who tells you how much to take has told a jury what the product is for.
The release does not name the compounds. We have not seen the trial exhibits, and we do not assume which peptides or other drugs were involved.
Why a verdict matters more than a plea.
We covered the Paradigm Peptides sentencing in August. That case ended in a guilty plea, and its centre was forged certificates of analysis and SARMs that tested as testosterone. Paradigm's owner admitted the research-use label was false. An admission is strong evidence, but it is a negotiated one.
Pinned Aminos is different in kind. The defendant contested the charges, a jury heard the evidence, and twelve people concluded that the research-use framing was a deception rather than a description. That is a finding of fact, not a concession, and it is the finding every gray-market seller relying on the same two sentences has to reckon with.
| Paradigm Peptides | Pinned Aminos | |
|---|---|---|
| How it ended | guilty plea | jury verdict |
| Core conduct | forged COAs, adulterated SARMs, false US-made claims | RUO disclaimer with dosing guidance, no prescriptions, imports |
| Scale stated | ~54,000 customers | >10,000 parcels, >$1.4 million |
| Sentence | 70 months (owner), 16 months (employee) | pending (owner), 3 years probation (co-defendant) |
| Venue | N.D. Indiana | D. Connecticut |
The same logic, now in two forums.
FDA's August 2026 warning letters treated dosing information, injection instructions and dose calculators on a vendor's website as evidence that the products were intended for human use, which is what makes them unapproved new drugs regardless of the label. That is an administrative finding. Pinned Aminos is the criminal version of the same inference: dosing guidance, wherever it is posted, establishes intent.
The practical consequence for a seller is that the disclaimer and the conduct are read together. A research-use label on a product page does not survive a Facebook group where the same seller explains protocols. Our enforcement timeline tracks how the agency's letters have moved from the label to the conduct behind it since 2024, and this verdict is the first point on that line where a jury, not a regulator, drew the conclusion.
What this case does not establish.
Three things, so the argument stays honest.
It does not show that every seller using a research-use disclaimer is committing fraud. The verdict turned on specific conduct: no prescriptions, foreign imports, and dosing directions from the sellers themselves. A seller that publishes no dosing, makes no health claims and cancels orders it suspects are for human use is not described by this record, and we score that posture separately on every vendor page.
It does not tell us what was sold. The release names no compounds, and we have not read the exhibits.
And it is not yet a sentence. Fields faces up to five years on the conspiracy count and up to twenty on the money-laundering count, but the number will be set by a judge, not by the maximums. We will update this page when it is.
What to take from it.
For a reader, the lesson is the one we keep returning to: the words on a label tell you what the seller wants a regulator to believe, and nothing about the material in the vial. The checks that hold are the ones that do not route through the seller, which we set out in the Paradigm piece and apply on every vendor audit.
For the market, the lesson is that "research use only" has now failed in front of a jury. It failed because the sellers wrote down what the products were for. Any seller still writing that down is building the prosecution's exhibit list.
Sources
- US Attorney's Office, District of Connecticut - Former Connecticut Resident Guilty of Operating Websites to Illegally Sell Misbranded and Unapproved Drugs, 21 September 2026 - primary source for the verdict, charges, conduct, scale, forfeiture, bond status and the co-defendant's plea and sentence
- Internal: Paradigm Peptides forged its COAs, FDA and Lilly letters, August 2026, FDA peptide enforcement 2024-2026
Frequently asked
What was Pinned Aminos convicted of?
Owner Ryan Fields was found guilty by a federal jury on 18 September 2026 of one count of conspiracy to introduce misbranded or unapproved drugs into interstate commerce and to smuggle goods into the United States, and one count of conspiracy to commit money laundering. The Justice Department says the operation shipped more than 10,000 parcels and took in more than $1.4 million between September 2021 and June 2023.
Has the Pinned Aminos owner been sentenced?
Not as of 13 October 2026. Fields was released on bond pending sentencing, and no sentencing date had been set. The conspiracy count carries up to five years and the money-laundering count up to twenty. His co-defendant, Lisa Mahan, pleaded guilty on 6 April 2026 and was sentenced on 13 August 2026 to three years of probation.
Does a "research use only" label protect a peptide seller?
Not when the seller's own conduct shows it intends human use. In this case the Justice Department said the disclaimer was there to mislead FDA, and the evidence that defeated it was the sellers' emails and Facebook posts giving customers dosing directions and health benefits. FDA's August 2026 warning letters used the same logic against dosing information on vendor sites. The label describes the seller's claim, not the seller's intent.
How is this different from the Paradigm Peptides case?
Paradigm's owner pleaded guilty, and the core of that case was forged lab certificates and products that tested as testosterone. Pinned Aminos went to trial, and the core of it was the research-use disclaimer paired with dosing guidance. A plea is an admission; a verdict is a finding by twelve people who heard the evidence. Both ended in federal convictions.